PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

被引：0
|
作者：
Schettini, F. [1 ]
Pascual, T. [1 ]
Chic, N. [1 ]
Conte, B. [2 ]
Martinez, O. [1 ]
Adamo, B. [1 ]
Vidal, M. [1 ]
Munoz, M. [1 ]
Fernandez-Martinez, A. [3 ]
Griguolo, G. [4 ]
Guarneri, V. [4 ]
Conte, P. F. [4 ]
De Placido, S. [5 ]
Carey, L. [6 ]
Perou, C. M. [7 ]
Prat, A. [1 ]
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[2] Univ Genoa, Osped Policlin San Martino, Med Oncol, Genoa, Italy
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol, Padua, Italy
[5] Azienda Univ Osped Federico II, Clin Med & Surg, Naples, Italy
[6] UNC, Lineberger Canc Ctr, Med, Div Hematol Oncol, Chapel Hill, NC USA
[7] UNC, Lineberger Canc Ctr, Genet, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
    Hohmann, Lennart
    Sigurjonsdottir, Kristin
    Campos, Ana Bosch
    Nacer, Deborah F.
    Veerla, Srinivas
    Rosengren, Frida
    Reddy, Poojaswini Thimmaraya
    Hakkinen, Jari
    Nordborg, Nicklas
    Vallon-Christersson, Johan
    Memari, Yasin
    Black, Daniella
    Bowden, Ramsay
    Davies, Helen R.
    Borg, Ake
    Nik-Zainal, Serena
    Staaf, Johan
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [32] A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab
    Chambers, J.
    Maxwell, A.
    Kingdon, S.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E106 - E106
  • [33] A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
    Piras, Marta
    Panebianco, Martina
    Garibaldi, Matteo
    Roberto, Michela
    Merlonghi, Gioia
    Pellegrini, Patrizia
    Marchetti, Paolo
    CURRENT ONCOLOGY, 2021, 28 (03) : 1957 - 1961
  • [34] Intratumoral and peritumoral MRI signatures of HER2-enriched subtype also predict pathological response to neoadjuvant chemotherapy in HER2+breast cancers
    Braman, Nathaniel
    Prasanna, Prateek
    Singh, Salendra
    Beig, Niha
    Gilmore, Hannah
    Etesami, Maryam
    Bates, David
    Gallagher, Katie
    Bloch, B. Nicolas
    Somlo, George
    Sikov, William
    Harris, Lyndsay
    Plecha, Donna
    Varadan, Vinay
    Madabhushi, Anant
    CANCER RESEARCH, 2018, 78 (04)
  • [35] Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
    Prat, Aleix
    Bianchini, Giampaolo
    Thomas, Marlene
    Belousov, Anton
    Cheang, Maggie C. U.
    Koehler, Astrid
    Gomez, Patricia
    Semiglazov, Vladimir
    Eiermann, Wolfgang
    Tjulandin, Sergei
    Byakhow, Mikhail
    Bermejo, Begona
    Zambetti, Milvia
    Vazquez, Federico
    Gianni, Luca
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 511 - 521
  • [36] Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
    Swain, Sandra M.
    Macharia, Harrison
    Cortes, Javier
    Dang, Chau
    Gianni, Luca
    Hurvitz, Sara A.
    Jackisch, Christian
    Schneeweiss, Andreas
    Slamon, Dennis
    Valagussa, Pinuccia
    du Toit, Yolande
    Heinzmann, Dominik
    Knott, Adam
    Song, Chunyan
    Cortazar, Patricia
    CANCERS, 2022, 14 (20)
  • [37] Impact of anthracyclines use on pathological complete response to neoadjuvant treatment in HER2-positive breast cancer
    Teixeira, C.
    Goncalves, M.
    Valente, A. C.
    Reis, J.
    Tavares, N.
    Augusto, I.
    Sousa, I.
    Almeida, D.
    Ribeiro, M. J.
    Barbosa, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 32 - 32
  • [38] Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
    Dieci, Maria Vittoria
    Conte, Pierfranco
    Bisagni, Giancarlo
    Bartolini, Stefania
    Frassoldati, Antonio
    Generali, Daniele
    Piacentini, Federico
    Griguolo, Gaia
    Tagliafico, Enrico
    Braso Maristany, Fara
    Chic, Nuria
    Pare, Laia
    Miglietta, Federica
    Vicini, Roberto
    D'Amico, Roberto
    Balduzzi, Sara
    Prat, Aleix
    Guarneri, Valentina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (01): : 69 - 80
  • [39] Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
    Zhang, Jie
    Yu, Yushuai
    Lin, Yuxiang
    Kang, Shaohong
    Lv, Xinyin
    Liu, Yushan
    Lin, Jielong
    Wang, Jun
    Song, Chuangui
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [40] Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
    Zhang, J.
    Yu, Y.
    Lin, Y.
    Kang, S.
    Lv, X.
    Liu, Y.
    Lin, J.
    Wang, J.
    Song, C.
    BREAST, 2021, 56 : S49 - S50
12345